Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market Intelligence.
On September 7, the U.S. Patent Office refused competitor Coherus's request for an inter partes review of AbbVie's U.S. Patent 9,085,619. The decision added strength to claims by AbbVie's management that it can keep Humira copy-cats out of the market in the U.S. until the end of 2022.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Amgen Inc. Stock
€356.75
0.380%
With 41 Buy predictions and 4 Sell predictions Amgen Inc. is one of the favorites of our community.
However, we have a potential of -5.82% for Amgen Inc. as the target price of 336 € is below the current price of 356.75 €.
